Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hereditary Angioedema - Type 1 Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT02584959
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
C1 esterase inhibitor [human] liquid, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

NCT01095510
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CINRYZE
Biological
Lead sponsor
Shire
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Colorado Springs, Colorado • Tampa, Florida • Chevy Chase, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

NCT01386658
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
icatibant
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Shreveport, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

NCT06467084
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 150 mg, KVD900 300 mg, KVD900 600 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
2 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

NCT05055258
View directory record Official record
Conditions
Angioedema, Hereditary, Types I and II
Interventions
KVD824, Placebo to KVD824
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Completed No phase listed Observational

Patient Registry Study of Berinert® in Normal Clinical Practice

NCT01108848
View directory record Official record
Conditions
Includes: Hereditary Angioedema
Interventions
Berinert® (C1 Esterase Inhibitor)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
34
States / cities
Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 28, 2026, 11:13 PM EDT
Active, not recruiting Phase 3 Interventional

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

NCT06634420
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
NTLA-2002, Normal Saline IV Administration
Biological
Lead sponsor
Intellia Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
navenibart, Placebo
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00262080
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS),
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00457015
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06343779
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 28, 2026, 11:13 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
12 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Little Rock, Arkansas • San Diego, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of STAR-0215 in Healthy Adult Participants

NCT05477160
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 28, 2026, 11:13 PM EDT
Recruiting Phase 3 Interventional

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT07298447
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
Donidalorsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Santa Monica, California • Miami, Florida • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Recruiting No phase listed Observational

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

NCT07001280
View directory record Official record
Conditions
Hereditary Angioedemas
Interventions
No intervention
Other
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
7
States / cities
Phoenix, Arizona • Miami, Florida • Saint Charles, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Angioedema Biomarker Research Study

NCT06210698
View directory record Official record
Conditions
Angioedema, Angioedemas, Hereditary, Urticaria, Mastocytosis, ACE Inhibitor-Induced Angioedema, C1 Inhibitor Deficiency, Systemic Mastocytoses, Indolent Systemic Mastocytosis
Interventions
Venipuncture
Diagnostic Test
Lead sponsor
Foundation For Rare Disease Research
Other
Eligibility
12 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Completed No phase listed Observational

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

NCT07009262
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Inapplicable
Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema

NCT05695248
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Navenibart
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

NCT05121376
View directory record Official record
Conditions
Hereditary Angioedema, HAE
Interventions
Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
Genetic
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

NCT05139810
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 28, 2026, 11:13 PM EDT
Active, not recruiting Phase 2 Interventional

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

NCT06007677
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
STAR-0215
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT02316353
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
C1-esterase inhibitor
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

NCT03712228
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Factor XIIa antagonist monoclonal antibody, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Orange, California • Walnut Creek, California • Centennial, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

NCT03472040
View directory record Official record
Conditions
Hereditary Angioedema, HAE, Prophylaxis
Interventions
BCX7353
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 28, 2026, 11:13 PM EDT